MMHU-2 funding will ensure that patients within the priority populations receive immediate care for acute and chronic conditions, including substance use disorder (SUD)/opioid use disorder (OUD), wherever it is sought in the service area and transitions to additional recovery services are managed and supported.
Subrecipients must develop and submit a fully implementable plan that details licensure enabling the MMHU-2 to dispense the three forms of U.S. Food and Drug Administration (FDA)-approved OUD medications (buprenorphine, naltrexone, and methadone), acquisition/lease of the vehicle(s) customized for providing services, and staff/personnel to support the MMHU-2.
MMHU-2 implementation plans will include the proposed services provided, their location(s), frequency, and the projected budget for medications and services not otherwise funded, as well as collaborate with oversight entities such as DEA and SUPR.
Important Dates
Technical Assistance Session October 28, 2024 at 1:00 p.m. CST.
Questions about MMHU-2 due November 29, 2024 at 5:00 p.m. CST.
Applications due December 13, 2024 at 5:00 p.m. CST.
Application Materials
Information about the Notice of Funding Opportunity is organized into four main topics: the NOFO, the application, the budget, and FAQs.
1. NOFO
The NOFO includes all program requirements and terms and conditions related to the award.